Healthcare Industry News: alpha-synuclein
News Release - October 16, 2020
Enterin Announces Appointment of New CEOPHILADELPHIA, Oct. 16, 2020 -- (Healthcare Sales & Marketing Network) -- Enterin, Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia and developing novel compounds to treat neurodegenerative diseases, announces the appointment of David McCullough as Chief Executive Officer.
Enterin's founders and chairmen, Michael Zasloff, MD, PhD and Denise Barbut MD, FRCP reciprocated the sentiment. They said, "We are delighted that David has agreed to join Enterin. His extensive experience in the pharmaceutical industry will supplement the scientific and medical expertise of the existing management team."
About Enterin Inc.
Enterin Inc. is the first company to develop novel compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Enterin Inc. is pioneering the medical community's understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut and the early onset and chronic progression of neurodegenerative disease. The lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson's disease. Enterin Inc. is now progressing ENT-01 through clinical trials in an attempt to reverse the neurologic symptoms of Parkinson's disease.
For more information, please visit www.enterininc.com.
Source: Enterin Inc
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.